Mancia G, Grassi G
Cattedra di Clinica Medica, Ospedale San Gerardo dei Tintori di Monza, MI.
Ann Ital Med Int. 2000 Jan-Mar;15(1):92-5.
Despite many outstanding favorable results obtained over the past 30-40 years in the treatment of hypertension, several goals of antihypertensive therapy remain unmet. One of them concerns the epidemiological evidence that only 25% of treated hypertensive patients have optimal blood pressure control. Clinical use of new antihypertensive drugs is aimed at achieving the above-mentioned goals, and in particular, at providing more effective blood pressure control, greater cardiovascular protection, and better patient compliance to antihypertensive drug treatment. This paper will examine the main clinical features of angiotensin II receptor blockers, highlighting the results of clinical studies performed thus far, and the main goals of ongoing clinical trials with these drugs. Finally, the role of these compounds in the therapeutic approach to the hypertensive state according to the recent guidelines of the World Health Organization/International Society of Hypertension will be outlined.
尽管在过去30到40年里高血压治疗取得了许多显著的良好效果，但抗高血压治疗的几个目标仍未实现。其中之一涉及流行病学证据，即只有25%接受治疗的高血压患者实现了最佳血压控制。新型抗高血压药物的临床应用旨在实现上述目标，特别是提供更有效的血压控制、更强的心血管保护以及更好的患者对降压药物治疗的依从性。本文将研究血管紧张素II受体阻滞剂的主要临床特征，突出迄今为止进行的临床研究结果以及这些药物正在进行的临床试验的主要目标。最后，将概述根据世界卫生组织/国际高血压学会最近的指南，这些化合物在高血压状态治疗方法中的作用。
